NEW YORK — UK immunodiagnostics firm Oncimmune said today that a distribution partner for its EarlyCDT Lung cancer assay has signed a sales and marketing agreement for the test with Spanish private healthcare organization Vithas Group.
EarlyCDT Lung measures levels of seven autoantibodies to tumor-associated antigens and is designed to detect all forms of lung cancer at any stage. Under a recently expanded agreement, Sabartech is the test's exclusive distributor in Spain and Portugal.
According to Oncimmune, Sabartech has struck a deal under which Vithas will promote the EarlyCDT Lung, as well as offer it as a screen for the early detection of lung cancer at its 48 hospitals and medical centers in Spain. Additional terms were not disclosed.
The deal, Oncimmune CEO Adam Hill said in a statement, "highlights the growing momentum behind our business and further validates our strategy of creating value through partnering to unlock the potential of the EarlyCDT portfolio."
Earlier this month, Oncimmune struck and exclusive commercial partnership for EarlyCDT Lung with R-Pharm covering Russia and member states of the Eurasian Customs Union. In June, Oncimmune sold off its US operations, along with the US rights to the test, to Biodesix.